Literature DB >> 26508480

Targeting epigenetic regulations in cancer.

Bo Ning1, Wenyuan Li2, Wei Zhao1, Rongfu Wang3.   

Abstract

Epigenetic regulation of gene expression is a dynamic and reversible process with DNA methylation, histone modifications, and chromatin remodeling. Recently, groundbreaking studies have demonstrated the importance of DNA and chromatin regulatory proteins from different aspects, including stem cell, development, and tumor genesis. Abnormal epigenetic regulation is frequently associated with diseases and drugs targeting DNA methylation and histone acetylation have been approved for cancer therapy. Although the network of epigenetic regulation is more complex than people expect, new potential druggable chromatin-associated proteins are being discovered and tested for clinical application. Here we review the key proteins that mediate epigenetic regulations through DNA methylation, the acetylation and methylation of histones, and the reader proteins that bind to modified histones. We also discuss cancer associations and recent progress of pharmacological development of these proteins.
© The Author 2015. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities:  

Keywords:  DNA methylation; anti-cancer drugs; epigenetic regulation; histone modification; inhibitors

Mesh:

Substances:

Year:  2015        PMID: 26508480      PMCID: PMC4689160          DOI: 10.1093/abbs/gmv116

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  158 in total

Review 1.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

2.  Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2.

Authors:  Pedro V Peña; Foteini Davrazou; Xiaobing Shi; Kay L Walter; Vladislav V Verkhusha; Or Gozani; Rui Zhao; Tatiana G Kutateladze
Journal:  Nature       Date:  2006-05-21       Impact factor: 49.962

Review 3.  Chromatin proteins and modifications as drug targets.

Authors:  Kristian Helin; Dashyant Dhanak
Journal:  Nature       Date:  2013-10-24       Impact factor: 49.962

4.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

Review 5.  Aberrant DNA methylation as a cancer-inducing mechanism.

Authors:  Manel Esteller
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

6.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

7.  AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Authors:  Robert W Wilkinson; Rajesh Odedra; Simon P Heaton; Stephen R Wedge; Nicholas J Keen; Claire Crafter; John R Foster; Madeleine C Brady; Alison Bigley; Elaine Brown; Kate F Byth; Nigel C Barrass; Kirsten E Mundt; Kevin M Foote; Nicola M Heron; Frederic H Jung; Andrew A Mortlock; F Thomas Boyle; Stephen Green
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

8.  MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Authors:  Marielle Fournel; Claire Bonfils; Yu Hou; Pu Theresa Yan; Marie-Claude Trachy-Bourget; Ann Kalita; Jianhong Liu; Ai-Hua Lu; Nancy Z Zhou; Marie-France Robert; Jeffrey Gillespie; James J Wang; Hélène Ste-Croix; Jubrail Rahil; Sylvain Lefebvre; Oscar Moradei; Daniel Delorme; A Robert Macleod; Jeffrey M Besterman; Zuomei Li
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

Review 9.  TET family proteins and their role in stem cell differentiation and transformation.

Authors:  Luisa Cimmino; Omar Abdel-Wahab; Ross L Levine; Iannis Aifantis
Journal:  Cell Stem Cell       Date:  2011-09-02       Impact factor: 24.633

10.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

View more
  27 in total

1.  Reshaping the Chromatin and Epigenetic Landscapes with Quantitative Mass Spectrometry.

Authors:  Michael P Washburn; Yingming Zhao; Benjamin A Garcia
Journal:  Mol Cell Proteomics       Date:  2016-01-26       Impact factor: 5.911

2.  Suberoylanilide Hydroxamic Acid (SAHA) Reduces Fibrosis Markers and Deactivates Human Stellate Cells via the Epithelial-Mesenchymal Transition (EMT).

Authors:  Merve Özel; Mevlut Baskol; Hilal Akalın; Gulden Baskol
Journal:  Cell Biochem Biophys       Date:  2021-03-10       Impact factor: 2.194

3.  Epigenetic Modulators as Potential Multi-targeted Drugs Against Hedgehog Pathway for Treatment of Cancer.

Authors:  Anshika N Singh; Neeti Sharma
Journal:  Protein J       Date:  2019-10       Impact factor: 2.371

4.  Identification of Epigenetic-Dysregulated lncRNAs Signature in Osteosarcoma by Multi-Omics Data Analysis.

Authors:  Junchao Huang; Jingwei Zhang; Haijun Xiao
Journal:  Front Med (Lausanne)       Date:  2022-06-16

5.  Transcriptome Profiling of N7-Methylguanosine Modification of Messenger RNA in Drug-Resistant Acute Myeloid Leukemia.

Authors:  Bing Zhang; Dong Li; Ran Wang
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

Review 6.  Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved.

Authors:  Karthigayan Shanmugasundaram; Karen Block
Journal:  Antioxid Redox Signal       Date:  2016-07-27       Impact factor: 8.401

Review 7.  Functions of RNA N6-methyladenosine modification in acute myeloid leukemia.

Authors:  Xue Zheng; Yuping Gong
Journal:  Biomark Res       Date:  2021-05-17

8.  Magnetofection based on superparamagnetic iron oxide nanoparticle-mediated low lncRNA HOTAIR expression decreases the proliferation and invasion of glioma stem cells.

Authors:  Kan Fang; Peifeng Liu; Suyan Dong; Yanjie Guo; Xinxin Cui; Xiaoying Zhu; Xuan Li; Lianghan Jiang; Te Liu; Yuncheng Wu
Journal:  Int J Oncol       Date:  2016-06-08       Impact factor: 5.650

Review 9.  The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis.

Authors:  Jiaming Su; Fei Wang; Yong Cai; Jingji Jin
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

10.  A vector platform for the rapid and efficient engineering of stable complex transgenes.

Authors:  Carsten Jäckel; Melanie Schmitt Nogueira; Nadja Ehni; Christiane Kraus; Julius Ranke; Maike Dohmann; Elfriede Noessner; Peter J Nelson
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.